GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cosciens Biopharma Inc (TSX:CSCI) » Definitions » ROIC %

Cosciens Biopharma (TSX:CSCI) ROIC % : -93.02% (As of Sep. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Cosciens Biopharma ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Cosciens Biopharma's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2024 was -93.02%.

As of today (2025-03-25), Cosciens Biopharma's WACC % is 8.25%. Cosciens Biopharma's ROIC % is -61.67% (calculated using TTM income statement data). Cosciens Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cosciens Biopharma ROIC % Historical Data

The historical data trend for Cosciens Biopharma's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosciens Biopharma ROIC % Chart

Cosciens Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.41 9.99 14.85 18.67 -23.08

Cosciens Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.43 -43.30 -33.73 -58.72 -93.02

Competitive Comparison of Cosciens Biopharma's ROIC %

For the Biotechnology subindustry, Cosciens Biopharma's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's ROIC % distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's ROIC % falls into.



Cosciens Biopharma ROIC % Calculation

Cosciens Biopharma's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-6.326 * ( 1 - 20.25% )/( (22.214 + 21.5)/ 2 )
=-5.044985/21.857
=-23.08 %

where

Cosciens Biopharma's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2024 is calculated as:

ROIC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-26.192 * ( 1 - 1.91% )/( (29.134 + 26.107)/ 2 )
=-25.6917328/27.6205
=-93.02 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosciens Biopharma  (TSX:CSCI) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cosciens Biopharma's WACC % is 8.25%. Cosciens Biopharma's ROIC % is -61.67% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cosciens Biopharma ROIC % Related Terms

Thank you for viewing the detailed overview of Cosciens Biopharma's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosciens Biopharma Business Description

Traded in Other Exchanges
Address
c/o Norton Rose Fulbright Canada LLP, 222 Bay Street, Suite 3000, Toronto, ON, CAN, M5K 1E7
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.
Executives
Dennis Turpin Director
Gilles Gagnon Director

Cosciens Biopharma Headlines

From GuruFocus

Ceapro Announces Grant of Stock Options

By Stock market mentor Stock market mentor 01-04-2023